It is suggested a promotive role in quantitative reduction of the BCR-ABL fusion gene by flumatinib even after flumatinib combined with chemotherapy, accompanied by the increased the MMR rate between groups with the extension of treatment time, which confirms the continuous effect of flumatinib on the molecular remission effect in Ph+ ALL patients. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.